19379A: Long-term, Open-label (dose-blinded), Extension study of Eptinezumab in Children and Adolescents with Chronic or Episodic Migraine

Grants and Contracts Details

StatusActive
Effective start/end date5/12/235/12/25

Funding

  • H. Lundbeck A/S: $11,393.00